2
@cphiww #cphiasean Organised By: Safe Water Gives Life Help CPhI support Global Angels: www.cphi.com/angels 6-8 April 2016 • Jakarta International Expo • Indonesia 01 Pharmaceutical market growth in Southeast Asia is projected to reach USD 23 billion in 2015, with average annual growth of 9.6%. In Indonesia, the region’s largest economy, annual growth is over 10% and the market is estimated to be USD 7.1 billion in 2015. Governments across Southeast Asia are introducing universal healthcare programs. This is driving rising demand for all categories of medicines, especially generic drugs. Since launching its mandatory healthcare coverage program (JKN) in 2014, Indonesia’s government healthcare spending has increased by 4%, and is forecast to reach USD 7.8 billion in 2016. 02 Implementation of the ASEAN Economic Community (AEC) by the end of 2015 will open up greater opportunities for trade and commerce among its member states. Healthcare, including pharmaceuticals, has been identified as a key sector where efforts to achieve harmonization of laws and standards will be concentrated. 03 Indonesia has eased investment rules, allowing foreign ownership of up to 85% in the pharmaceutical sector, and is encouraging further investment growth in this sector. 04 CPhI South East Asia and its co-located events InnoPack and P-MEC provide the perfect platform to connect with and do business in the pharmaceutical industry of the Southeast Asia region International Exhibitor Contact: Francis Onochie E. [email protected] T. +31 (0)20 40 99 529 South East Asia Exhibitor Contact: Maria Lioe E. [email protected] T. +62 21 2930 5959 Indonesia imports over 90% of the pharmaceutical ingredients it uses. The value of imports during the first half of 2015 saw a staggering rise of 17%, to USD 296 million. 05 Book Your Stand Indonesia – Your Gateway to South East Asia’s Pharma Market

Indonesia – Your Gateway to South East Asia’s Pharma ... · PDF filePharmacist 5% Business Development 16% Senior Management API’s, 16% Pharmaceutical Packaging, 10% Excipients/Formulation,

  • Upload
    danganh

  • View
    215

  • Download
    1

Embed Size (px)

Citation preview

@cphiww #cphiasean

Organised By:

Safe Water Gives Life Help CPhI support Global Angels: www.cphi.com/angels

6-8 April 2016 • Jakarta International Expo • Indonesia

01 Pharmaceutical market growth in Southeast Asia is projected to reach USD 23 billion in 2015, with average annual growth of 9.6%. In Indonesia, the region’s largest economy, annual growth is over 10% and the market is estimated to be USD 7.1 billion in 2015.

Governments across Southeast Asia are introducing universal healthcare programs. This is driving rising demand for all categories of medicines, especially generic drugs. Since launching its mandatory healthcare coverage program (JKN) in 2014, Indonesia’s government healthcare spending has increased by 4%, and is forecast to reach USD 7.8 billion in 2016.

02

Implementation of the ASEAN Economic Community (AEC) by the end of 2015 will open up greater opportunities for trade and commerce among its member states. Healthcare, including pharmaceuticals, has been identified as a key sector where efforts to achieve harmonization of laws and standards will be concentrated.

03

Indonesia has eased investment rules, allowing foreign ownership of up to 85% in the pharmaceutical sector, and is encouraging further investment growth in this sector.

04

CPhI South East Asia and its co-located events InnoPack and P-MEC provide the perfect platform to connect with and do business in the pharmaceutical industry of the Southeast Asia region

International Exhibitor Contact: Francis Onochie E. [email protected] T. +31 (0)20 40 99 529

South East Asia Exhibitor Contact: Maria Lioe E. [email protected] T. +62 21 2930 5959

Indonesia imports over 90% of the pharmaceutical ingredients it uses. The value of imports during the first half of 2015 saw a staggering rise of 17%, to USD 296 million.

05

Book Your Stand

Indonesia – Your Gateway to South East Asia’s Pharma Market

3 Pharma Events under 1 roofCPhI, P-MEC & InnoPack South East Asia -The 3 most important sectors of pharma manufacturing:ingredients, machinery & equipment and packaging.

The marketplace for pharma ingredients manufacturers, suppliers and buyers.

Showcases the newest pharma machinery, equipment and technology.

Brings the latest innovations in packaging and drug delivery systems.

Visitors Statistics

Visitor’s Product Main Areas of Interest

Visitors of top pharma companies that attended Abbot Indonesia, Actavis Indonesia, Bayer, Boehringer Ingelheim, Dankos, Darya Varia, GlaxoSmithKline, Indofarma, Pfizer and more...

http://www.cphi.com/asean

CPhI South East Asia Forum - Over 50 tracks covering the latest topics in the pharmaceutical industry will be presented at the forum by industry experts

Innovation Gallery - Showcasing the most innovative and revolutionary products within pharma

Business Matchmaking Program - Free service to pre-arrange meetings with buyers and suppliers to optimize your time.

CPhI South East Asia: over 6,000 attendees meeting more than 260 exhibitors from 31 countries

P-MEC Route - Daily tour guiding visitors to exhibitors who showcase pharmaceutical machineries and technologies

Health ingredients (Hi) South East Asia - This is an exciting new addition to the region’s most comprehensive pharmaceutical event. Health ingredients (Hi) South East Asia focuses on the health, functional and natural ingredients that are used in pharmaceuticals, health products, foods and cosmetics.

Visitors’ top job positions

Visitors by country (outside Indonesia)

Hong KongKorea

ChinaJapan

MalaysiaThailand

IndiaVietnam

SingaporePhilippines

30%QA & QC

23%

DepartmentHead

7%R&D

12%

Scientist, Chemist,Pharmacist

5%

BusinessDevelopment

16%

SeniorManagement

API’s, 16%

Pharmaceutical Packaging, 10%

Excipients/Formulation, 9%

Finished Formulation, 9%

Pharmaceutical Technology, Laboratory and Analytical

Equipment, 9%

Biopharmaceuticals, 8%

Natural Extract, 7%Analytical & Lab Services, 6%Bio Services, 5%

Contract Services, 5 %

Pre Clinical Trials, Clinical Trials Stages 1 -4, CRO, Clinical Data, 5%

Fine Chemicals and Intermediates, 5%

Others, 6%

NEW

NEW

NEW

NEW

NEW